TY  - JOUR
IS  - 23
A1  - Uras, Giuseppe
A1  - Li, Xinuo
A1  - Manca, Alessia
A1  - Pantaleo, Antonella
A1  - Bo, Marco
A1  - Xu, Jinyi
A1  - Allen, Stephanie
A1  - Zhu, Zheying
PB  - MDPI
Y1  - 2022/12/01/
UR  - https://doi.org/10.3390/ijms232314794
KW  - Alzheimer; AChE; GSK3-?; inhibitors; Tau; hyperphosphorylation
TI  - Development of p-Tau Differentiated Cell Model of Alzheimer?s Disease to Screen Novel Acetylcholinesterase Inhibitors
N2  - Alzheimer?s disease (AD) is characterized by an initial accumulation of amyloid plaques and neurofibrillary tangles, along with the depletion of cholinergic markers. The currently available therapies for AD do not present any disease-modifying effects, with the available in vitro platforms to study either AD drug candidates or basic biology not fully recapitulating the main features of the disease or being extremely costly, such as iPSC-derived neurons. In the present work, we developed and validated a novel cell-based AD model featuring Tau hyperphosphorylation and degenerative neuronal morphology. Using the model, we evaluated the efficacy of three different groups of newly synthesized acetylcholinesterase (AChE) inhibitors, along with a new dual acetylcholinesterase/glycogen synthase kinase 3 inhibitor, as potential AD treatment on differentiated SH-SY5Y cells treated with glyceraldehyde to induce Tau hyperphosphorylation, and subsequently neurite degeneration and cell death. Testing of such compounds on the newly developed model revealed an overall improvement of the induced defects by inhibition of AChE alone, showing a reduction of S396 aberrant phosphorylation along with a moderate amelioration of the neuron-like morphology. Finally, simultaneous AChE/GSK3 inhibition further enhanced the limited effects observed by AChE inhibition alone, resulting in an improvement of all the key parameters, such as cell viability, morphology, and Tau abnormal phosphorylation.
VL  - 23
ID  - discovery10184217
N1  - Copyright © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
SN  - 1661-6596
JF  - International Journal of Molecular Sciences
EP  - 18
AV  - public
ER  -